VP of Clinical Operations transitions to consultant role after FDA setback
GRCE sits 28% above its 52-week low of $1.79 on light trading volume (0.4× avg).
Summary
Grace Therapeutics' Vice President of Clinical Operations, Carrie D'Andrea, is stepping down from her executive role but will continue to provide clinical development and NDA-related consulting services for 12 months.
Key Events · Executive and Board Changes · GRCE
-
Executive Departure
Carrie D'Andrea, Vice President of Clinical Operations, will cease serving in her executive role effective June 5, 2026.
-
Transition to Consulting Role
Ms. D'Andrea has entered into a 12-month Consulting Agreement with the company to provide clinical development and NDA-related services at a fee of $250 per hour.
-
Continued Option Vesting
Her stock option awards will continue to vest and remain exercisable during the term of the Consulting Agreement.
Analysis · GRCE · Life Sciences
This change in leadership for a critical function like clinical operations is notable, especially following the recent FDA Complete Response Letter for GTx-104. While Ms. D'Andrea is departing her executive role, the company has secured her expertise for another year through a consulting agreement, which is a pragmatic move to maintain continuity during a challenging regulatory period. The continued vesting of her stock options incentivizes her ongoing engagement.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 29.5% of the 1672 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.22%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GRCE was trading at $2.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $35.6M. The 52-week trading range was $1.79 to $5.18. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.